Triple
T10214570
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Inflectra |
E242408
|
entity |
| Predicate | hasActiveSubstance |
P69332
|
FINISHED |
| Object | infliximab-dyyb |
E850004
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: infliximab-dyyb | Statement: [Inflectra, hasActiveSubstance, infliximab-dyyb]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: infliximab-dyyb Context triple: [Inflectra, hasActiveSubstance, infliximab-dyyb]
-
A.
infliximab-dyyb
chosen
Infliximab-dyyb is a monoclonal antibody biosimilar to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
E.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasActiveSubstance Context triple: [Inflectra, hasActiveSubstance, infliximab-dyyb]
-
A.
hasAddictiveSubstance
Indicates that an entity contains or involves a substance capable of causing addiction in those who use or consume it.
-
B.
hasFictionalSubstance
Indicates that one entity includes, contains, or involves a fictional or imaginary substance as part of its composition, setting, or narrative.
-
C.
hasDrug
chosen
Indicates that an entity possesses, is treated with, or is associated with a particular drug.
-
D.
usedSubstance
Indicates that an entity has consumed, applied, or otherwise made use of a particular substance.
-
E.
acceptsSubstance
Indicates that an entity receives, takes in, or allows the use of a specified substance.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381ae26c48190985abd0e25ee5d04 |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d3aa273bdc8190bc4cf67a7923cebc |
completed | April 6, 2026, 12:42 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d6a7f6730081908b941eaeb6c00993 |
completed | April 8, 2026, 7:09 p.m. |
| PD | Predicate disambiguation | batch_69d39559e5ac8190b88eca75956b7e6a |
completed | April 6, 2026, 11:13 a.m. |
Created at: April 6, 2026, 11:04 a.m.